MX2018009341A - Formulaciones tamponadas para una mayor estabilidad de anticuerpos. - Google Patents
Formulaciones tamponadas para una mayor estabilidad de anticuerpos.Info
- Publication number
- MX2018009341A MX2018009341A MX2018009341A MX2018009341A MX2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- antibody stability
- enhanced antibody
- buffer formulations
- salt
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229960002964 adalimumab Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 159000000021 acetate salts Chemical class 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001483 arginine derivatives Chemical class 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 150000002411 histidines Chemical class 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290654P | 2016-02-03 | 2016-02-03 | |
| PCT/US2017/016040 WO2017136433A1 (en) | 2016-02-03 | 2017-02-01 | Buffer formulations for enhanced antibody stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009341A true MX2018009341A (es) | 2019-05-15 |
Family
ID=58046768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009341A MX2018009341A (es) | 2016-02-03 | 2017-02-01 | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11285210B2 (enExample) |
| EP (1) | EP3411401A1 (enExample) |
| JP (1) | JP7084308B2 (enExample) |
| CN (1) | CN109563161A (enExample) |
| AU (1) | AU2017213775A1 (enExample) |
| CA (1) | CA3013336A1 (enExample) |
| MX (1) | MX2018009341A (enExample) |
| WO (1) | WO2017136433A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6526025B2 (ja) | 2013-10-16 | 2019-06-05 | オンコバイオロジクス，インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
| EP2946766B1 (en) * | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| TW202042840A (zh) * | 2019-01-11 | 2020-12-01 | 南韓商三星Ｂｉｏｅｐｉｓ股份有限公司 | 包含抗體的醫藥組成物、包含其的裝置、及其用途 |
| CA3155065A1 (en) * | 2019-09-19 | 2021-03-25 | Innovent Biologics (Suzhou) Co., Ltd. | Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease |
| US12435154B2 (en) | 2020-05-08 | 2025-10-07 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| US20240052026A1 (en) * | 2020-12-22 | 2024-02-15 | Bio-Thera Solutions, Ltd. | Stable antibody formulation, preparation method therefor, and applications thereof |
| GB202115127D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115121D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2101337A1 (en) | 1991-02-01 | 1992-08-02 | Stephan D. Glenn | Method of producing f(ab')2 fragments of immunoglobulins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| KR20130001318A (ko) | 2002-07-19 | 2013-01-03 | 애보트 바이오테크놀로지 리미티드 | ＴＮＦα 관련 질환의 치료 |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US8227241B2 (en) | 2004-03-12 | 2012-07-24 | Unigene Laboratories, Inc. | Bacterial host cell for the direct expression of peptides |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| TW200719913A (en) | 2005-03-08 | 2007-06-01 | Pharmacia & Upjohn Co Llc | Anti-madcam antibody compositions |
| CN102961746B (zh) | 2005-05-16 | 2016-06-15 | 艾伯维生物技术有限公司 | TNFα抑制剂治疗腐蚀性多关节炎的用途 |
| JP5442251B2 (ja) | 2005-05-26 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | 拡張可能な発酵方法 |
| EP2390267B1 (en) | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Stable and soluble antibodies inhibiting TNF(alpha) |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20070796A1 (es) | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| TWI424161B (zh) | 2005-11-01 | 2014-01-21 | Abbvie Biotechnology Ltd | 利用生物標記診斷關節黏連脊椎炎之方法及組合物 |
| NZ611859A (en) | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
| EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
| EP2703010A3 (en) | 2006-04-10 | 2014-08-06 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of rheumatoid arthritis |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| JP5437633B2 (ja) | 2006-09-11 | 2014-03-12 | 株式会社 免疫生物研究所 | モノクローナル抗体およびその用途 |
| SG174804A1 (enExample) | 2006-09-13 | 2011-10-28 | Abbott Lab | |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2500416A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| CA2667655A1 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
| CN101652379B (zh) | 2007-03-30 | 2014-05-14 | Abbvie公司 | 用于增加宿主细胞中重组蛋白表达的重组表达载体元件(reves) |
| KR101574355B1 (ko) | 2007-04-26 | 2015-12-11 | 추가이 세이야쿠 가부시키가이샤 | 고농도 아미노산 함유 배지를 사용한 세포의 배양 방법 |
| US8092998B2 (en) | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| JP2010535771A (ja) | 2007-08-08 | 2010-11-25 | アボット・ラボラトリーズ | 抗体を結晶化させるための組成物及び方法 |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| NZ585702A (en) | 2007-11-30 | 2013-08-30 | Abbott Lab | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2009073805A2 (en) | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| AU2009204863B2 (en) | 2008-01-15 | 2015-07-16 | AbbVie Deutschland GmbH & Co. KG | Powdered protein compositions and methods of making same |
| CA2711962A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Laboratories | Improved mammalian expression vectors and uses thereof |
| EP2081025B1 (en) | 2008-01-15 | 2010-03-10 | Universiteit Utrecht Holding B.V. | Method for determining the amino acid sequence of peptides |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| WO2009118662A2 (en) | 2008-03-24 | 2009-10-01 | Abbott Biotechnology Ltd. | Methods and compositions for treating bone loss |
| ES2458541T5 (en) | 2008-05-02 | 2025-08-04 | Seagen Inc | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
| NZ592096A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Antibodies that bind to il-12 and methods of purifying the same |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| BRPI0919979A2 (pt) | 2008-10-29 | 2015-12-15 | Wyeth Llc | formulações de moléculas de ligação de antígeno de domínio único |
| AU2009319856A1 (en) | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
| KR20120034593A (ko) | 2009-03-09 | 2012-04-12 | 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 | 위암 진단용 단백질 마커의 동정 |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| SG176251A1 (en) | 2009-06-02 | 2011-12-29 | Regeneron Pharma | Fucosylation-deficient cells |
| EP2438185A4 (en) | 2009-06-05 | 2016-10-05 | Momenta Pharmaceuticals Inc | METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS |
| EP2473191B1 (en) | 2009-09-04 | 2017-08-23 | XOMA Technology Ltd. | Antibody coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CN107693791B (zh) | 2010-02-26 | 2022-06-07 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US20110301342A1 (en) | 2010-05-18 | 2011-12-08 | Abbott Laboratories, Inc. | Apparatus and process for purification of proteins |
| WO2011150110A1 (en) | 2010-05-25 | 2011-12-01 | Genentech, Inc. | Methods of purifying polypeptides |
| CN105056232A (zh) | 2010-06-03 | 2015-11-18 | 阿布维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
| CN103201003B (zh) | 2010-09-20 | 2016-04-13 | Abbvie公司 | 采用模拟移动床色谱纯化抗体 |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| SG189872A1 (en) | 2010-10-11 | 2013-06-28 | Abbvie Inc | Processes for purification of proteins |
| MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
| WO2012091124A1 (ja) | 2010-12-28 | 2012-07-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| IL315908A (en) | 2011-07-01 | 2024-11-01 | Amgen Inc | Mammalian cell culture |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013052710A1 (en) | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
| TW201326207A (zh) | 2011-10-24 | 2013-07-01 | Abbvie Inc | 抗ｔｎｆ免疫結合物 |
| US20140288278A1 (en) | 2011-10-31 | 2014-09-25 | Joseph Nti-Gyabaah | Chromatography process for resolving heterogeneous antibody aggregates |
| WO2013114165A1 (en) | 2012-01-30 | 2013-08-08 | Dr Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased afucosylation content |
| WO2013114164A1 (en) | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| JP2015519382A (ja) | 2012-06-12 | 2015-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療用抗体のための医薬処方物 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| LT2892550T (lt) | 2012-09-07 | 2020-04-10 | Coherus Biosciences, Inc. | Stabilios adalimumabo vandeninės kompozicijos |
| JP5874587B2 (ja) | 2012-09-10 | 2016-03-02 | 株式会社島津製作所 | アミノ酸配列解析方法及び装置 |
| NO2760138T3 (enExample) | 2012-10-01 | 2018-08-04 | ||
| WO2014062535A1 (en) | 2012-10-15 | 2014-04-24 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2938323A2 (en) | 2012-12-28 | 2015-11-04 | Abbott Cardiovascular Systems, Inc. | Therapeutic compositions comprising antibodies |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| KR20150129033A (ko) | 2013-03-14 | 2015-11-18 | 애브비 인코포레이티드 | 저 산성 종 조성물 및 이의 제조 및 사용 방법 |
| US20140271633A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Mammalian cell culture performance through surfactant supplementation of feed media |
| WO2014175164A1 (ja) | 2013-04-25 | 2014-10-30 | 株式会社カネカ | Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子 |
| WO2014182658A1 (en) | 2013-05-06 | 2014-11-13 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
| AR096713A1 (es) | 2013-06-25 | 2016-01-27 | Cadila Healthcare Ltd | Proceso de purificación para anticuerpos monoclonales |
| EP3114476A4 (en) | 2013-10-03 | 2017-11-01 | Bioanalytix, Inc. | Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic |
| JP6526025B2 (ja) | 2013-10-16 | 2019-06-05 | オンコバイオロジクス，インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015140700A1 (en) | 2014-03-19 | 2015-09-24 | Dr. Reddy's Laboratories Limited | Cell culture process |
| LT2946765T (lt) * | 2014-05-23 | 2016-11-25 | Ares Trading S.A. | Skysta farmacinė kompozicija |
| HUP1400510A1 (hu) | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| CN105044222B (zh) | 2014-12-19 | 2017-09-12 | 浙江辉肽生命健康科技有限公司 | 生物活性多肽的分析测试和鉴定方法 |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| CN105779394B (zh) | 2015-03-20 | 2020-03-24 | 广东东阳光药业有限公司 | 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法 |
| WO2017120359A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition |
| MX2018008447A (es) | 2016-01-06 | 2019-05-30 | Oncobiologics Inc | Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. |
| MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
| CN109073655A (zh) | 2016-02-04 | 2018-12-21 | 安口生物公司 | 鉴定和分析蛋白的氨基酸序列的方法 |
-
2017
- 2017-02-01 MX MX2018009341A patent/MX2018009341A/es unknown
- 2017-02-01 WO PCT/US2017/016040 patent/WO2017136433A1/en not_active Ceased
- 2017-02-01 US US16/072,991 patent/US11285210B2/en active Active
- 2017-02-01 EP EP17705527.4A patent/EP3411401A1/en not_active Withdrawn
- 2017-02-01 AU AU2017213775A patent/AU2017213775A1/en not_active Abandoned
- 2017-02-01 JP JP2018540113A patent/JP7084308B2/ja active Active
- 2017-02-01 CN CN201780019727.6A patent/CN109563161A/zh active Pending
- 2017-02-01 CA CA3013336A patent/CA3013336A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3013336A1 (en) | 2017-08-10 |
| US11285210B2 (en) | 2022-03-29 |
| US20190030163A1 (en) | 2019-01-31 |
| AU2017213775A1 (en) | 2018-08-16 |
| JP2019504086A (ja) | 2019-02-14 |
| JP7084308B2 (ja) | 2022-06-14 |
| CN109563161A (zh) | 2019-04-02 |
| EP3411401A1 (en) | 2018-12-12 |
| WO2017136433A1 (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009341A (es) | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| IL280467A (en) | Antibody constructs for cldn18.2 and cd3 | |
| IL287025A (en) | Systems and methods to classify antibodies | |
| MX374124B (es) | Formulaciones de tampón para la estabilidad de anticuerpo mejorada. | |
| EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
| HRP20210924T1 (hr) | Agonist glukokortikoidnog receptora i njegovi imunokonjugati | |
| MA53905A (fr) | Anticorps stabilisant trem2 | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| MY191169A (en) | Anti-fcrh5 antibodies | |
| MA52212A (fr) | Anticorps multivalent | |
| MA71409A (fr) | Constructions d'anticorps pour dll3 et cd3 | |
| MX395147B (es) | Formulación de anticuerpo anti-cgrp. | |
| MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
| BR112016025291A2 (pt) | conjugados de anticorpo anti-ptk7-fármaco | |
| PL3576788T3 (pl) | Kompozycja farmaceutyczna o niskim ph zawierająca konstrukty przeciwciał angażujących komórki t | |
| UY40974A (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
| MX385853B (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
| EP4070818A3 (en) | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy | |
| IL262266A (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| MX2012013268A (es) | Formulaciones de anticuerpos de alta concentracion. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques |